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AbstrAct
Introduction Only a limited number of meta-analyses 
providing risk curve functions of dose–response 
relationships between various smoking-related variables 
and cancer-specific risk are available.
Methods and analysis To identify all relevant original 
publications on the issue, we will conduct a series of 
comprehensive systematic reviews based on three 
subsequent literature searches: (1) an umbrella 
review, to identify meta-analyses, pooled analyses and 
systematic reviews published before 28 April 2017 on 
the association between cigarette smoking and the risk 
of 28 (namely all) malignant neoplasms; (2) for each 
cancer site, an updated review of original publications on 
the association between cigarette smoking and cancer 
risk, starting from the last available comprehensive 
review identified through the umbrella review; and (3) a 
review of all original articles on the association between 
cigarette smoking and site-specific cancer risk included 
in the publications identified through the umbrella 
review and the updated reviews. The primary outcomes 
of interest will be (1) the excess incidence/mortality 
of various cancers for smokers compared with never 
smokers; and (2) the dose–response curves describing 
the association between smoking intensity, duration and 
time since stopping and incidence/mortality for various 
cancers. For each cancer site, we will perform a meta-
analysis by pooling study-specific estimates for smoking 
status. We will also estimate the dose–response curves 
for other smoking-related variables through random-
effects meta-regression models based on a non-linear 
dose–response relationship framework.
Ethics and dissemination Ethics approval is not 
required for this study. Main results will be published 
in peer-reviewed journals and will also be included in a 
publicly available website. We will provide therefore the 
most complete and updated estimates on the association 
between various measures of cigarette smoking and site-
specific cancer risk. This will allow us to obtain precise 
estimates on the cancer burden attributable to cigarette 
smoking.
trial registration number This protocol was registered 
in the International Prospective Register of Systematic 
Reviews (CRD42017063991).
IntroductIon
In 1950, Ernst Wynder and Evards Graham1 
and Richard Doll and Bradford Hill2 first 
reported an association between tobacco 
smoking and lung cancer risk. Over the subse-
quent 65 years, thousands of studies systemat-
ically confirmed this association and found 
that tobacco smoking also increases the risk 
of several other neoplasms.3 In 2004, tobacco 
smoking has been classified as carcinogenic 
to humans (group 1) by the International 
Agency for Research on Cancer (IARC),3 
which provided evidence on the causal rela-
tionship between cigarette smoking and 
cancer of the lung, oral cavity, nasal cavity 
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Protocol
strengths and limitations of this study
 ► This study represents the most complete and 
updated review on the association between cigarette 
smoking and site-specific cancer risk.
 ► We will not conduct a systematic review of the entire 
scientific literature on the issue, but we will rather 
use an original and innovative approach combining 
an umbrella review and traditional systematic 
reviews.
 ► We will carry out dose–response analyses using 
two-steps random-effects meta-regression models 
in order to examine potential non-linear relationships 
between smoking-related variables and the risk of 
cancer.
 ► We will not systematically consider the assignment 
of a quality score to all original publications for each 
cancer site.
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and paranasal sinuses, nasopharynx, oropharynx, hypo-
pharynx, larynx, oesophagus, stomach, pancreas, liver, 
kidney, ureter, urinary bladder, cervix and myeloid 
leukaemia.3 The results on the association between (ciga-
rette) smoking and other cancer sites, including cancers 
of the breast and endometrium, remain conflicting.3
Since the late 1980s, publications reporting results 
from systematic reviews and meta-analyses, the large 
majority of which were unnecessary and misleading, 
rapidly increased.4 Although the effects of cigarette 
smoking on cancer incidence and/or mortality have been 
largely investigated, only a limited number of systematic 
reviews/meta-analyses are available on the quantifica-
tion of the dose–response relationship between selected 
smoking-related variables, including smoking intensity, 
duration, pack-years and time since quitting, and the risk 
of cancer. More importantly, just a few meta-analyses, if 
any, provided the cancer-specific risk curve functions of 
the dose–response relationships. Dose–response data, 
however, are crucial to provide reliable and accurate 
estimates of the cancer burden due to smoking, both at 
individual level—absolute cancer incidence/mortality 
obtained through lung cancer risk assessment models 
and risk charts5 6; and at population level—smoking-at-
tributable deaths.7 8 Currently, the methods developed to 
quantify cancer burden due to smoking use cancer-spe-
cific estimates of relative risks (RR) according to tobacco 
smoking derived from a few large cohorts, mainly from 
the USA.9 The use of these cohorts to derive RRs may 
lead to validity problems when applying these estimates 
to other populations with different smoking patterns.7 10 
Furthermore, these RRs are often estimated after allow-
ance for a limited number of sociodemographic charac-
teristics, excluding potentially important confounding 
variables, such as alcohol drinking.
Using an original and innovative approach, which 
combines an umbrella review11 and traditional system-
atic reviews, we aim at providing a comprehensive and 
updated picture of the association between various smok-
ing-related variables and the risk of all cancers. We will 
be able to estimate the most robust cancer-specific RRs, 
obtained from the existing scientific literature, possibly 
derived after adjustment for relevant covariates. More-
over, for each cancer site, we will be able to provide the 
risk curves that best describe the dose–response effect of 
smoking intensity, smoking duration, pack-years and time 
since stopping smoking on cancer risk.
MEthods
The present cancer-specific systematic reviews/meta-anal-
yses will be based on the following three subsequent 
literature searches on the association between cigarette 
smoking and cancer risk:
1. umbrella review: a systematic review to identify 
published meta-analyses, pooled analyses and 
systematic reviews providing data on the association 
between cigarette smoking and cancer risk;
2. update of available cancer-specific reviews: for each 
cancer site, the conduction of a systematic review of 
studies providing original data (including pooled 
analyses on individual participants’ data) on the asso-
ciation between cigarette smoking and cancer-specific 
risk, starting from the last available comprehensive 
review publication identified through the umbrella 
review (point 1);
3. review of all original publications: a review of all 
original articles on the association between cigarette 
smoking and site-specific cancer risk included in the 
cancer-specific review publications identified through 
the umbrella review (point 1) or identified through 
the update of the available reviews (point 2).
The design of the present systematic reviews was devel-
oped following the Preferred Reporting Items for System-
atic review and Meta-Analyses (PRISMA) guidelines12 and 
its extension for protocols (PRISMA-P).13 14 This protocol 
was registered in the International Prospective Register of 
Systematic Reviews on 4 May 2017 (registration number: 
CRD42017063991).
umbrella review
Search strategy
We will conduct a systematic literature search to identify 
all published meta-analyses, pooled analyses and system-
atic reviews providing data on the association between 
cigarette smoking and the risk of various cancers. Litera-
ture search strategy will include combinations of medical 
subjects headings (MeSH) and text words related to 
cancer and tobacco or smoking, and will be restricted to the 
following publication types: meta-analyses, pooled anal-
yses and systematic reviews. No restriction on cancer site 
or on publication date will be applied. The following 
databases will be used: MEDLINE, Embase, Institute for 
Scientific Information (ISI) Web of Science (WoS) and 
Cochrane Database of Systematic Reviews (CDSR). The 
search strings to be used in various databases are reported 
in (online supplementary appendix 1). To ensure liter-
ature saturation, reference lists of selected relevant 
publications identified through the search will also be 
checked. Besides the publications found through the 
databases searches, we will also consider the reviews of 
the literature on tobacco smoking provided within the 
IARC monographs volume 833 and volume 100E15 and 
the Surgeon General Report,16 three reports of known 
importance providing data on the association between 
tobacco smoking and various cancer sites.
Eligibility criteria
Study design
We will include meta-analyses, pooled analyses and system-
atic reviews of observational studies providing measures 
of RRs between cigarette smoking and cancer risk. Orig-
inal observational studies (eg, case–control, cohort or 
cross-sectional studies) will be excluded. Reports, letters 
to the editor, book chapters, conference proceedings, 
dissertations and theses will not be considered.
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Conditions
We will consider publications providing data on the 
following 28 (namely all) malignant neoplasms: cancer of 
lip, oral cavity and pharynx (International Classification of 
Diseases; ICD-10: C00-C14), nasopharynx (C11), oesoph-
agus (C15), stomach (C16), colon (C18), rectum and anus 
(C19-C21), liver (C22), gall bladder (C23-C24), pancreas 
(C25), larynx (C32), lung trachea and bronchus (C33-
C34), bone (C40-C41), melanoma of skin (C43), meso-
thelioma (C45), breast (C50), cervix uteri (C53), corpus 
uteri (C54), ovary (C56), prostate (C61), testis (C62), 
kidney (C64), bladder (C67), brain, central nervous system 
(C70-C72), thyroid (C73), Hodgkin's lymphoma (C81), 
non-Hodgkin’s lymphoma (C82-C86, C96), multiple 
myeloma (C88-C90) and leukaemia (C91-C95). We will 
also consider review publications on groups of cancers 
(eg, head and neck, upper aerodigestive tract or intestinal 
cancers). Studies specifically based on benign neoplasms, 
such as colorectal polyps, acoustic neuroma and menin-
gioma, and neuroendocrine tumours, will be excluded.
Participants
We will include review publications providing data 
on humans, in the general population. We will there-
fore exclude review publications based on patients 
with cancer or other diseases (ie, reporting data on the 
effect of smoking on the prognosis of the disease), or 
on subgroups of the population with selected lifestyle 
habits or other characteristics (eg, populations limited 
to alcohol drinkers or tobacco smokers). No restriction 
will be applied according to age of participants at cancer 
incidence or mortality given that practically all studies 
providing data on the association between cigarette 
smoking and cancer risk are based on adults only.
Exposures
We will include all review publications providing data on 
the use of cigarettes in the general population. Publica-
tions focused on the use of tobacco products other than 
cigarettes (eg, pipe, smokeless tobacco, cigar, water pipe, 
electronic cigarettes) or on the exposure to secondhand 
smoke will be excluded.
Outcomes
The primary outcomes of interest will be (1) the excess 
incidence and/or mortality of various cancers in current/
former/ever smokers compared with never smokers; 
and (2) the dose–response curves describing the associ-
ation between cigarette smoking duration, intensity and 
time since stopping and incidence and/or mortality for 
various cancers.
Languages
We will include only articles published in English 
language.
Study selection
All the review publications found in various electronic 
databases through the above-mentioned search strategy 
will be uploaded in an EndNote library (EN1), and dupli-
cate records will be deleted. Titles and/or abstracts of the 
meta-analyses, pooled analyses and systematic reviews will 
be screened independently by two reviewers (AL, GP) 
to exclude publications that will not meet the eligibility 
criteria. The full text of the remaining review publica-
tions will be retrieved and independently assessed for 
eligibility by the two reviewers. Discrepancies between 
the two reviewers will be discussed and solved. In case of 
disagreement, a third reviewer (SG) will help to find a 
final decision. Other available reports will also be inte-
grated in the same EN1 library.
Quality assessment
Assessment of the quality of various review publica-
tions is out of the scope of the present systematic 
review. Thus, no quality score will be assigned to the 
publications. No review publication will be excluded a 
priori for weakness of design or data quality.
Data extraction and management
A standardised form in Microsoft (MS) Excel will be 
used to extract data from each identified review publi-
cation. Relevant information will include first author, 
year of publication, type of study (ie, meta-analysis, 
pooled analysis or systematic review), cancer site(s) 
and/or subsite(s), endpoint (ie, incidence and/or 
mortality), and other information about the meth-
odology of studies included in the reviews (eg, study 
design, country(ies) of study conduction, number 
of studies considered in and overall population 
size). Data will be extracted from each included 
meta-analysis, pooled analysis or systematic review by 
one reviewer and verified by a second reviewer. Any 
disagreement between the two reviewers will be solved 
by consensus. Otherwise, a third reviewer will help 
to find a final decision. After data extraction, publi-
cations will be grouped according to the considered 
cancer site.
Preliminary umbrella review
In April 2017, we already conducted a preliminary 
umbrella review through which we identified the 
meta-analyses, pooled analyses and systematic reviews 
on the association between smoking and cancer risk 
published before 28 April 2017. Within the comprehen-
sive literature search, we found a total of 1430 publi-
cations from the four considered databases (726 from 
MEDLINE, 316 from Embase, 376 from ISI WoS and 12 
from CDSR; figure 1). After the exclusion of duplicates 
(n=542) and ineligible papers (n=716), and after the 
inclusion of three important reports,3 15 16 we obtained 
a total of 175 relevant publications (ie, 107 meta-anal-
yses, 52 pooled analyses and 16 systematic reviews) on 
the association between smoking and risk of various 
neoplasms.
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Figure 1 Flow chart for the selection of papers on tobacco 
smoking and cancer risk (published before 28 April 2017) 
in the umbrella review. CDSR, Cochrane Database of 
Systematic Reviews; IARC, International Agency for Research 
on Cancer; ISI WoS, Institute for Scientific Information Web of 
Science.
update of the available cancer-specific reviews
Search strategy
For each of the 28 cancer sites previously described in 
the umbrella review, we will identify the last available 
comprehensive systematic review or meta-analysis on the 
association with cigarette smoking. We will then update 
the identified cancer-specific review through the conduc-
tion of a systematic literature search on all observational 
studies (eg, case–control, cohort and nested case–
control studies) providing original data on the associa-
tion between cigarette smoking and site-specific cancer 
risk, and published after the year of publication of the 
most recent article included in the last comprehensive 
review. Only studies published in English language will 
be considered.
The literature search strategy will be conducted in 
Medline and Embase, and will include combinations 
of MeSH terms and text words related to site-specific 
cancer and tobacco or smoking (see online supplementary 
appendix 2).
Eligibility criteria
Study design
We will include original observational studies (eg, 
case–control, cohort, nested case–control studies or 
pooled analysis of individual participant data) providing 
measures of RRs of the association between cigarette 
smoking and site-specific cancer risk. Reports, book chap-
ters, conference proceedings, dissertations and theses will 
not be considered. We will exclude case–control studies 
using patients with cancer or other chronic diseases as 
comparison group.
Comparator
Never smokers are our comparators. We will in fact 
consider, as the measure of association, the RRs of smok-
ing-related variables compared with never smokers and we 
will therefore exclude the RRs considering non-smokers 
(never and former smokers combined) as reference 
category.
Eligibility criteria for conditions, participants, exposures 
and outcomes are those reported also for the umbrella 
review.
Study selection
For each cancer site, we will upload all the original publi-
cations found using the above-mentioned search strategy 
in cancer-specific EndNote libraries (EN2_1-EN2_28), 
and we will delete the identified duplicates. Titles and/
or abstracts of original articles will be screened inde-
pendently by two reviewers (AL, GP) to exclude publi-
cations that do not meet the inclusion criteria outlined 
above. The full text of the remaining original publications 
will be retrieved and independently assessed for eligibility 
by the two reviewers. Discrepancies on the assessment 
between the two reviewers will be discussed and solved. 
In case of disagreement, a third reviewer (SG) will help to 
find a final decision.
review of all original publications
For each cancer site, we will upload in an EndNote 
library (EN3_1-EN3_28) all the original publications 
obtained from the 28 cancer-specific reviews identified 
in the umbrella review (point 1). In the same EndNote 
libraries, we will add the original publications obtained 
from the corresponding updates of the reviews (point 
2), and duplicate publications will be deleted. The full 
text of all the retained original publications will be 
retrieved. Non-English reports, unpublished studies, 
conference proceedings, dissertations and theses will 
be excluded.
Figure 2 shows the flow chart we will consider for each 
of the 28 cancer-specific reviews. For each cancer site, 
original publications from both the umbrella review and 
the update of the reviews will be considered.
Quality assessment
Although quality assessment of original publications is out 
of the scope of the present systematic review, we do not 
exclude the possibility, at least for selected neoplasms, to 
assign a quality score to the original publications in order 
to conduct sensitivity analyses excluding the publications 
with a relatively low quality. In this case, the quality (risk 
of bias) for each observational study will be assessed using 
the Newcastle-Ottawa Scale for observational studies.17
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Figure 2 Flow chart for each of the 28 cancer-specific reviews on tobacco smoking. IARC, International Agency for Research 
on Cancer.
Data extraction and management
For each cancer site, two standardised forms in MS Excel 
will be used to collect relevant information on the study 
design and the risk estimates from the original publica-
tions. A first form will be used to extract data related to 
the study design, including first author, year of publica-
tion, journal, country, study name, period and design of 
study, outcome and sample size. In the second form we 
will collect the exposure categories (ie, smoking status, 
intensity, duration, pack-years, age at starting, time since 
stopping) and corresponding RR estimates (or other esti-
mates, such as ORs and HRs) and 95% confidence inter-
vals (CI). The number of cases in each exposure category 
and covariates used in the model will be also collected. 
When the results of the same study have been published 
in more than one original publication, only data from the 
most recent and/or complete article will be retained and 
reported in the second Excel form.
Data analysis
For each cancer site, we will pool all the RRs or other 
risk estimates (eg, HRs and ORs) in order to obtain 
the association between smoking status (separately for 
current, former and ever compared with never smokers) 
and the risk of cancer. Because cancer is a relatively rare 
outcome, we assume that ORs, risk ratios and rate ratios 
are all comparable estimates of the RR. Heterogeneity 
between studies will be assessed using the Cochran Q 
test and the I2 statistics, that is, the proportion of total 
variation contributed by between-study heterogeneity.18 
As we anticipated between-study heterogeneity, we will 
present pooled RRs from random-effects models using 
the DerSimonian and Laird moment estimator of the 
between-study variance component.19 However, if no 
heterogeneity between study is detected, pooled esti-
mates from the random-effects model will correspond to 
those deriving from the fixed-effect model.
When RRs are not reported for ever smokers, but 
only separately for current and former smokers, we will 
use the method for pooling non-independent estimates 
described by Hamling et al20 to obtain RRs for ever 
smokers besides those for current and former compared 
with never smokers. This method uses the number of 
subjects exposed to different levels of smoking and 
non-exposed subjects, and the corresponding risk esti-
mates and 95% CIs, to derive a set of pseudo-numbers of 
cases and controls/subjects at risk, by taking into account 
the correlation between the original estimates due to the 
common reference group. The obtained pseudo-num-
bers will be used to compute the new adjusted RRs and 
95% CIs. This methodology will also be used to convert 
RR estimates when the reference category considered in 
the study is not represented by never smokers.
For smoking intensity, duration and time since stop-
ping smoking, we will compute pooled RRs according to 
various categories of the considered smoking-related vari-
ables (eg, low, intermediate, high cigarette consumption). 
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Moreover, we will carry out dose–response analyses using 
two-steps random-effects meta-regression models in order 
to examine potential non-linear relationships between 
those variables and the risk of cancer. In particular, we 
will consider a method providing the best fitting two-term 
fractional polynomial model,21 and a method modelling 
the considered smoking-related variables using restricted 
cubic splines.22
If the necessary data are available, we will consider to 
further conduct separate analyses by sex, study period, 
geographical area and income (defined on the basis of 
per capita gross domestic product).
Analyses will be conducted using SAS V.9.4 software and 
R V.3.3.0 software (R Development Core Team, 2008), in 
particular meta and dosresmeta packages.
EthIcs And dIssEMInAtIon
Ethics
This review does not require approval from an ethics 
committee since no individual-level patients’ data will be 
collected.
Implications and dissemination
Through these systematic reviews and meta-analyses, 
we will provide the most complete and updated esti-
mates on the association between cigarette smoking 
and site-specific cancer risk. These estimates will be 
used to quantify the cancer burden due to cigarette 
smoking at both individual and population levels. 
This information is essential to guide policy deci-
sions to control tobacco smoking and improve cancer 
prevention.
Given the relevance and originality of this project, 
we plan to publish results from the meta-analyses in 
peer-reviewed journals, considering either single 
cancer sites or various apparatus or tracts. A final 
publication will provide the summary results for all 
cancers. We will also include the main results of our 
systematic reviews and meta-analyses in a publicly 
available website. Readers will have the possibility to 
contact us to communicate possible lacks or updates.
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